Impax Asset Management Group
BMY icon

Impax Asset Management Group’s Bristol-Myers Squibb BMY Stock Holding History

Impax Asset Management Group’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.29M Sell
103,727
-40,950
-28% -$2.39M 0.04% 189
2025
Q4 		$7.8M Sell
144,677
-3,367
-2% -$162K 0.05% 173
2025
Q3 		$6.68M Sell
148,044
-4,251
-3% -$199K 0.04% 173
2025
Q2 		$7.05M Buy
152,295
+20,864
+16% +$1.02M 0.04% 173
2025
Q1 		$8.02M Sell
131,431
-16,815
-11% -$980K 0.05% 156
2024
Q4 		$8.38M Sell
148,246
-100,826
-40% -$5.63M 0.04% 174
2024
Q3 		$12.9M Sell
249,072
-2,574
-1% -$121K 0.05% 143
2024
Q2 		$10.5M Sell
251,646
-996
-0.4% -$44.6K 0.04% 158
2024
Q1 		$13.7M Buy
252,642
+66,792
+36% +$3.4M 0.05% 145
2023
Q4 		$9.54M Sell
185,850
-92,216
-33% -$4.84M 0.04% 179
2023
Q3 		$16.1M Sell
278,066
-7,511
-3% -$460K 0.07% 128
2023
Q2 		$18.3M Sell
285,577
-402,674
-59% -$27M 0.07% 128
2023
Q1 		$47.7M Buy
688,251
+36,679
+6% +$2.59M 0.2% 104
2022
Q4 		$46.9M Buy
651,572
+127,114
+24% +$9.58M 0.21% 101
2022
Q3 		$37.3M Buy
524,458
+156,789
+43% +$11.4M 0.19% 98
2022
Q2 		$28.3M Sell
367,669
-263,726
-42% -$20.1M 0.14% 106
2022
Q1 		$46.1M Sell
631,395
-78,223
-11% -$5.25M 0.19% 92
2021
Q4 		$44.2M Buy
709,618
+65,395
+10% +$3.84M 0.16% 94
2021
Q3 		$38.1M Buy
644,223
+80,722
+14% +$5.32M 0.16% 97
2021
Q2 		$37.7M Hold
563,501
– – 0.17% 92
2021
Q1 		$35.6M Buy
563,501
+152,621
+37% +$9.5M 0.18% 82
2020
Q4 		$25.5M Hold
410,880
– – 0.16% 85
2020
Q3 		$24.8M Buy
410,880
+60,000
+17% +$3.61M 0.22% 78
2020
Q2 		$20.6M Hold
350,880
– – 0.21% 79
2020
Q1 		$19.6M Buy
350,880
+62,800
+22% +$3.84M 0.26% 78
2019
Q4 		$18.5M Buy
288,080
+12,868
+5% +$737K 0.21% 87
2019
Q3 		$14M Hold
275,212
– – 0.18% 93
2019
Q2 		$12.5M Buy
275,212
+83,200
+43% +$3.88M 0.16% 98
2019
Q1 		$9.16M Buy
+192,012
New +$9.56M 0.13% 121

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Impax Asset Management Group's BMY Position: Q1 2026 in Review

Impax Asset Management Group reduced its Bristol-Myers Squibb (BMY) stake by 28% in Q1 2026, selling an estimated $2.39M and leaving 103,727 shares worth $6.29M. The position accounts for 0.04% of the portfolio, ranked #189.

Impax Asset Management Group first reported a position in BMY in Q1 2019 and has held it in 29 quarters since. The position peaked at $47.7M in Q1 2023. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Impax Asset Management Group held 103,727 shares of Bristol-Myers Squibb worth $6.29M as of Q1 2026.
  • Impax Asset Management Group sold 40,950 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.39M.
  • Bristol-Myers Squibb made up 0.04% of Impax Asset Management Group's portfolio in Q1 2026, its #189 holding.
  • Impax Asset Management Group first reported a position in Bristol-Myers Squibb in Q1 2019 and has held it in 29 quarters since.
  • Impax Asset Management Group's Bristol-Myers Squibb position peaked at $47.7M in Q1 2023.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Impax Asset Management Group's 13F filing for Q1 2026, filed 12 May 2026.